Zobrazeno 1 - 10
of 1 202
pro vyhledávání: '"G, von Minckwitz"'
Autor:
Alison Conlin, Thomas Boulet, Georg Kunz, J.C. Alcedo, Andrea Fontana, Irene Wapnir, Norman Wolmark, Xavier Pivot, Max S. Mano, Adam Brufsky, S. Loibl, D. Tesarowski, Chunyan Song, Bella Kaufman, Youngsen Yang, Melanie Smitt, Mahasti Saghatchian, Martina Zimovjanova, Michael Untch, G. von Minckwitz, Jonathan Polikoff, Charles E. Geyer, S. Kuemmel, H. Liu, Eleftherios P. Mamounas, John Hackmann, Lisa H. Lam, C.-S. Huang, T. Kuehn, Michael P. DiGiovanna
Publikováno v:
Annals of Oncology. 32:1005-1014
Background In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::576b1e3095951bd70b19d13844d2b56c
https://doi.org/10.1016/j.annonc.2021.04.011
https://doi.org/10.1016/j.annonc.2021.04.011
Autor:
S. Loibl, M. Untch, N. Burchardi, J. Huober, B.V. Sinn, J.-U. Blohmer, E.-M. Grischke, J. Furlanetto, H. Tesch, C. Hanusch, K. Engels, M. Rezai, C. Jackisch, W.D. Schmitt, G. von Minckwitz, J. Thomalla, S. Kümmel, B. Rautenberg, P.A. Fasching, K. Weber, K. Rhiem, C. Denkert, A. Schneeweiss
Publikováno v:
Annals of Oncology. 33:743-744
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acdf832b91a5fe0265e5014723d991c1
https://doi.org/10.1016/j.annonc.2022.04.003
https://doi.org/10.1016/j.annonc.2022.04.003
Autor:
Jörg Thomalla, G. von Minckwitz, J Huober, EM Grischke, S. Loibl, Hans Tesch, C. Jackisch, Wolfgang D. Schmitt, PA Fasching, Knut Engels, Andreas Schneeweiss, Beate Rautenberg, Carsten Denkert, Karsten Weber, Michael Untch, J-U Blohmer, Nicole Burchardi, S Kümmel, Mahdi Rezai, Bruno Valentin Sinn, Claus Hanusch, Jenny Furlanetto, K Rhiem
Publikováno v:
Annals of Oncology. 30:1279-1288
Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f02ea6adb032e9fb2991d7caf1f0dbaf
https://doi.org/10.1093/annonc/mdz158
https://doi.org/10.1093/annonc/mdz158
Autor:
Michael Untch, T Karn, Ahmed El-Balat, Andreas Schneeweiss, G. von Minckwitz, Sven Becker, U. Holtrich, Christos Hatzis, Achim Rody, Karsten Weber, Tobias Meissner, L Pusztai, C. Solbach, S. Loibl, Bruno Valentin Sinn, C Denkert, Valentina Nekljudova
Publikováno v:
Cancer Research. 79:P3-10
Background: We have previously shown that expression of the IL8/VEGFA-metagene eliminates the good prognostic effect of TILs in TNBC (PMID 21978456, 28750120). We also showed that the VEGFA metagene predicted response to neoadjuvant bevacizumab in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15631c3f52270ac4eff49aa2d0677632
https://doi.org/10.1158/1538-7445.sabcs18-p3-10-01
https://doi.org/10.1158/1538-7445.sabcs18-p3-10-01
Autor:
Keyur Mehta, Hans Tesch, Michael Untch, K Rhiem, J-U Blohmer, J Huober, C. Solbach, Andreas Schneeweiss, Mahdi Rezai, Christoph Salat, S. Loibl, PA Fasching, G. von Minckwitz, C. Jackisch, C Denkert, Valentina Nekljudova, Fenja Seither, Claus Hanusch
Publikováno v:
Cancer Research. 79:P2-08
Background Even though patients with a pCR following neoadjuvant chemotherapy have an excellent prognosis still some of these patients will eventually relapse. A better identification of pts with an increased risk of relapse despite a pCR would be he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87b63ccbca95a71202b5bf4c0aa132f
https://doi.org/10.1158/1538-7445.sabcs18-p2-08-01
https://doi.org/10.1158/1538-7445.sabcs18-p2-08-01
Autor:
Andrew T. Chan, B. Barnett, H. Iwata, Noelia Martínez, T Fujita, A Murias Rosales, A Luczak, Marc Buyse, Fan Xu, Manuel Ruiz-Borrego, M. Gnant, M Spencer, Beverly Moy, F.A. Holmes, HS Rugo, Suzette Delaloge, Janine Mansi, Serafin Morales, M. Martin, Carlos Barrios, T Galeano, S.R.D. Johnston, C. Jackisch, Bent Ejlertsen, Cristina Saura, S Chia, Jo Chien, M Bhandari, G. von Minckwitz
Publikováno v:
Cancer Research. 79:P2-13
Background: The international, randomized, placebo-controlled phase III ExteNET trial showed that 1 year (yr) of neratinib 240 mg/day after trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (iDFS) in 2840 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51130fb376a5f8a2c42ffa501755614c
https://doi.org/10.1158/1538-7445.sabcs18-p2-13-01
https://doi.org/10.1158/1538-7445.sabcs18-p2-13-01
Autor:
T Karn, C. Jackisch, Andreas Schneeweiss, Karsten Weber, Jörg Thomalla, H. P. Sinn, Frederick Klauschen, Bruno Valentin Sinn, Denise Treue, Claus Hanusch, B Felder, G. von Minckwitz, D. M. Zahm, Nicole Burchardi, F Marmé, PA Fasching, C Denkert, S. Loibl, J Huober, Michael Untch, K Rhiem, J-U Blohmer
Publikováno v:
Cancer Research. 79:PD2-07
Background: The GeparNuevo trial showed a numerical increase in the pCR rate to 53% vs 44%; p=0.281 compared to placebo in TNBC with the addition of the anti-PD-L1 antibody durvalumab to a neoadjuvant anthracycline-taxane containing chemotherapy (Loi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dba06a0dfdaf25422264657d44f19da8
https://doi.org/10.1158/1538-7445.sabcs18-pd2-07
https://doi.org/10.1158/1538-7445.sabcs18-pd2-07
Autor:
Lisa H. Lam, Michael DiGiovanna, Melanie Smitt, C-S Huang, S. Loibl, Andrés Redondo, E Rota Caremoli, PA Fasching, Claudia Arce-Salinas, G. von Minckwitz, Charles E. Geyer, Pia Wuelfing, Eleftherios P. Mamounas, Irene Wapnir, Alison Conlin, William Jacot, Haiyan Wu, Andreas Schneeweiss, P Rastogi, Mano, J.P. Crown, Stina M. Singel, Holger Fischer, Michael Untch, C. Jackisch, D. Tesarowski, Norman Wolmark, Hannah Douthwaite, Zhimin Shao
Publikováno v:
Cancer Research. 79:GS1-10
Background: Patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy have a high risk of recurrence and death. The current standard of care is continuation of the sam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d27d732d92057012e3bebe5d6be165d5
https://doi.org/10.1158/1538-7445.sabcs18-gs1-10
https://doi.org/10.1158/1538-7445.sabcs18-gs1-10
Autor:
Christian Fesl, Y Devyatko, Sean Ferree, Martin Filipits, Christian F. Singer, Marija Balic, Florian Fitzal, M. Gnant, G. von Minckwitz, Zsuzsanna Bago-Horvath, L Soelkner, B Gray, Günther G. Steger, Richard Greil
Publikováno v:
Cancer Research. 79:P1-17
Background: Therapeutic recommendations for adjuvant treatment of hormone-receptor positive breast cancer patients depend on the individual recurrence risk. A number of genomic assays introduced to achieve this goal, but it's still questioned if they
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73f95bbb8389b47d44581e20384b446b
https://doi.org/10.1158/1538-7445.sabcs18-p1-17-05
https://doi.org/10.1158/1538-7445.sabcs18-p1-17-05
Autor:
Christian Schem, Julia Reid, A-R Hartman, Kirsten Timms, Christoph Salat, Peter A. Fasching, C. Jackisch, D. M. Zahm, Kerstin Rhiem, Carsten Denkert, Rita K. Schmutzler, Valentina Nekljudova, EP Elkin, Sherko Kümmel, B. Lederer, Mahdi Rezai, Bernd Gerber, Andreas Schneeweiss, S. Loibl, S. Penn, Karsten Weber, G. von Minckwitz, Michael Untch, Stefan Paepke, Eric Hahnen, Sascha D. Braun, J-U Blohmer, Peter Klare
Publikováno v:
Annals of Oncology. 29:2341-2347
Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c10f334c82035ea3159b3cfff03892b
https://doi.org/10.1093/annonc/mdy460
https://doi.org/10.1093/annonc/mdy460